Literature DB >> 3044368

Cellular mechanism of action by a novel vasoconstrictor endothelin in cultured rat vascular smooth muscle cells.

Y Hirata1, H Yoshimi, S Takata, T X Watanabe, S Kumagai, K Nakajima, S Sakakibara.   

Abstract

Specific binding sites for synthetic porcine endothelin (pET), a novel potent vasoconstrictor peptide isolated from the supernatant of cultured porcine endothelial cells, and its effects on cytosolic free Ca2+ concentrations ([Ca2+]i) and phosphatidylinositol (PI) response were studied in cultured rat aortic vascular smooth muscle cells (VSMC). Binding of 125I-labeled-pET to rat VSMC was time- and temperature-dependent and the cell-bound 125I-labeled-pET was resistant to dissociate. Scatchard analysis of binding studies indicated the presence of a single class of high-affinity binding sites: the apparent Kd was 2-4 X 10(-10) M and the maximal binding capacity was 11,000-13,000 sites/cell. The binding was highly specific for pET because neither well-recognized vasoconstrictors, peptide neurotoxins, nor Ca2+-channel blockers affected the binding. pET dose-dependently (10(-9)-10(-7) M) induced a transient and sustained increase in [Ca2+]i in fura-2-loaded cells of which effect was largely dependent on extracellular Ca2+, whereas it had no significant effect on PI response in 3H-myoinositol-prelabeled cells. The present data clearly demonstrates the presence of specific receptors for pET distinct from those of the well-recognized vasoconstrictors and voltage-dependent Ca2+-channels in cultured rat VSMC, and suggest that pET-induced increase in [Ca2+]i is involved in the mechanism of its vasoconstriction.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3044368     DOI: 10.1016/0006-291x(88)90220-3

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  55 in total

1.  Endothelin-like pulmonary vasoconstrictor peptide release by alpha-thrombin.

Authors:  D G Moon; M J Horgan; T T Andersen; S R Krystek; J W Fenton; A B Malik
Journal:  Proc Natl Acad Sci U S A       Date:  1989-12       Impact factor: 11.205

2.  Effects of endothelin on the mechanical activity and cytosolic calcium level of various types of smooth muscle.

Authors:  K Sakata; H Ozaki; S C Kwon; H Karaki
Journal:  Br J Pharmacol       Date:  1989-10       Impact factor: 8.739

3.  Specific binding of endothelin on human vascular smooth muscle cells in culture.

Authors:  M Clozel; W Fischli; C Guilly
Journal:  J Clin Invest       Date:  1989-05       Impact factor: 14.808

4.  Endothelin activates voltage-dependent Ca2+ current by a G protein-dependent mechanism in rabbit cardiac myocytes.

Authors:  M R Lauer; M D Gunn; W T Clusin
Journal:  J Physiol       Date:  1992-03       Impact factor: 5.182

5.  Modulation of the [Ca2+] sensitivity of myosin phosphorylation in intact swine arterial smooth muscle.

Authors:  C M Rembold
Journal:  J Physiol       Date:  1990-10       Impact factor: 5.182

6.  The pharmacological properties of the peptide, endothelin.

Authors:  R M Eglen; A D Michel; N A Sharif; S R Swank; R L Whiting
Journal:  Br J Pharmacol       Date:  1989-08       Impact factor: 8.739

7.  Reversal of established responses to endothelin-1 in vivo and in vitro by the endothelin receptor antagonists, BQ-123 and PD 145065.

Authors:  T D Warner; G H Allcock; J R Vane
Journal:  Br J Pharmacol       Date:  1994-05       Impact factor: 8.739

8.  Identification of the Ca2+ current activated by vasoconstrictors in vascular smooth muscle cells.

Authors:  C Van Renterghem; M Lazdunski
Journal:  Pflugers Arch       Date:  1994-11       Impact factor: 3.657

9.  Endothelin- and oxytocin-induced calcium signaling in cultured human myometrial cells.

Authors:  E Maher; A Bardequez; J P Gardner; L Goldsmith; G Weiss; M Mascarina; A Aviv
Journal:  J Clin Invest       Date:  1991-04       Impact factor: 14.808

10.  Endothelin action in rat liver. Receptors, free Ca2+ oscillations, and activation of glycogenolysis.

Authors:  C Serradeil-Le Gal; C Jouneaux; A Sanchez-Bueno; D Raufaste; B Roche; A M Préaux; J P Maffrand; P H Cobbold; J Hanoune; S Lotersztajn
Journal:  J Clin Invest       Date:  1991-01       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.